The Cape Chacma baboon is not suitable for evaluating human targeted anti-GPVI agents

References

• Achar SA, Kundu S, Norcross WA. Diagnosis of acute coronary syndrome. Am Fam Physician 2005;72:119–126
   PubMed Web of Science ®Google Scholar
• Cannon CP, Brindis RG, Chaitman BR, Cohen DJ, Cross CJT Jr, Drozda JP Jr, Fesmire FM, Fintel DJ, Fonarow GC, Fox KA, et al. 2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: A report of the American College of Cardiology Foundation/ American Heart Association Task Force on Clinical Data Standards (Writing committee to develop acute coronary syndromes and coronary artery disease clinical data standards). Circulation 2013;127:1052–1089
   PubMed Web of Science ®Google Scholar
• Cook DJ, Teves L, Tymianski M. Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain. Nature 2012;483:213–217
   PubMed Web of Science ®Google Scholar
• Mason RG, Wolf RH, Zucker WH, Shinoda BA, Mohammad SF. Effects of antithrombotic agents evaluated in a nonhuman primate vascular shunt model. Am J Pathol 1976;83:557–568
   PubMed Web of Science ®Google Scholar
• Zahid M, Mangin P, Loyau S, Hechler B, Billiald P, Gachet C, Jandrot-Perrus M. The future of glycoprotein VI as an antithrombotic target. J Throm Haemost 2012;10:2418–2427
   PubMed Web of Science ®Google Scholar
• Sugiyama T, Okuma M, Ushikubi F, Sensaki S, Kanaji K, Uchino H. A novel platelet aggregating factor found in a patient with defective collagen-induced platelet aggregation and autoimmune thrombocytopenia. Blood 1987;69:1712–1720
   PubMed Web of Science ®Google Scholar
• Moroi M, Jung SM, Okuma M, Shinmyozu K. A patient with platelets deficient in glycoprotein VI that lack both collagen-induced aggregation and adhesion. J Clin Invest 1989;84:1440–1445
   PubMed Web of Science ®Google Scholar
• Takahashi H, Moroi M. Antibody against platelet membrane glycoprotein VI in a patient with systemic lupus erythematosus. Am J Hematol 2001;67:262–267
   PubMed Web of Science ®Google Scholar
• Nurden P, Jandrot-Perrus M, Combrié R, Winckler J, Arocas V, Lecut C, Pasquet JM, Kunicki TJ, Nurden AT. Severe deficiency of glycoprotein VI in a patient with gray platelet syndrome. Blood 2004;104:107–114
   PubMed Web of Science ®Google Scholar
• Boylan B, Chen H, Rathore V, Paddock C, Salacz M, Friedman KD, Curtis BR, Stapleton M, Newman DK, Kahn ML, et al. Anti-GPVI-associated ITP: An acquired platelet disorder caused by autoantibody-mediated clearance of the GPVI/FcRγ-chain complex from the human platelet surface. Blood 2004;104:1350–1355
   PubMed Web of Science ®Google Scholar
• Kojima H, Moroi M, Jung SM, Goto S, Tamura N, Kozuma Y, Suzukawa K, Nagasawa T. Characterization of a patient with glycoprotein (GP) VI deficiency possessing neither anti-GPVI autoantibody nor genetic aberration. J Thromb Haemost 2006;4:2433–2442
   PubMed Web of Science ®Google Scholar
• Hermans C, Wittevrongel C, Thys C, Smethurst PA, Van Geet C, Freson K. A compound heterozygous mutation in glycoprotein VI in a patient with a bleeding disorder. J Thromb Haemost 2009;7:1356–1363
   PubMed Web of Science ®Google Scholar
• Miura Y, Takahashi T, Jung SM, Moroi M. Analysis of the interaction of platelet collagen receptor glycoprotein VI (GPVI) with collagen: A dimeric form of GPVI, but not the monomeric form, shows affinity to fibrous collagen. J Biol Chem 2002;277:46197–46204
   PubMed Web of Science ®Google Scholar
• Lecut C, Feeney LA, Kingsbury G, Hopkins J, Lanza F, Gachet C, Villeval JL, Jandrot-Perrus M. Human platelet glycoprotein VI function is antagonized by monoclonal antibody-derived Fab fragments. J Thromb Haemost 2003;1:2653–2662
   PubMed Web of Science ®Google Scholar
• Massberg S, Konrad I, Bültmann A, Schulz C, Münch G, Peluso M, Lorenz M, Schneider S, Besta F, Müller I, et al. Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo. FASEB J 2004;18:397–399
   PubMedGoogle Scholar
• Grüner S, Prostredna M, Koch M, Miura Y, Schulte V, Jung SM, Moroi M, Nieswandt B. Relative antithrombotic effect of soluble GPVI dimer compared with anti-GPVI antibodies in mice. Blood 2005;105:1492–1499
   PubMed Web of Science ®Google Scholar
• Matsumoto Y, Takizawa H, Nakam K, Gong X, Yamada Y, Tandon NN, Kambayashi J. Ex vivo evaluation of anti-GPVI antibody in Cynomolgus monkeys: Dissociation between anti-platelet aggregatory effect and bleeding time. J Thromb Haemost 2006;96:167–175
   Web of Science ®Google Scholar
• Ohlmann P, Hechler B, Ravanat C, Loyau S, Herrenschmidt N, Wanert F, Jandrot-Perrus M, Gachet C. Ex vivo inhibition of thrombus formation by an anti-glycoprotein VI Fab fragment in non-human primates without modification of glycoprotein VI expression. J Thromb Haemost 2008;6:1003–1011
   PubMed Web of Science ®Google Scholar
• Takayama H, Hosaka Y, Nakayama K, Shirakawa K, Naitoh K, Matsusue T, Shinozaki M, Honda M, Yatagai Y, Kawahara T, et al. A novel antiplatelet antibody therapy that induces cAMP-dependent endocytosis of the GPVI/Fc receptor γ-chain complex. J Clin Invest 2008;118:1785–1795
   PubMed Web of Science ®Google Scholar
• Janse van Rensburg WJ, Roodt JP, Lamprecht S, Meiring SM, Badenhorst PN. Tirofiban versus abciximab: Tirofiban is administered at suboptimal dosages when evaluated in an arterial thrombosis model in non-human primates. Clin Exp Med 2012;12:257–263
   PubMed Web of Science ®Google Scholar
• Cauwenberghs N, Meiring M, Vauterin S, Van Wyk V, Lamprecht S, Roodt JP, Novák L, Harsfalvi J, Deckmyn H, Kotzé HF. Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in nonhuman primates. Arterioscler Thromb Vasc Biol 2000;20:1347–1353
   PubMed Web of Science ®Google Scholar
• Fontayne A, Meiring M, Lamprecht S, Roodt J, Demarsin E, Barbeaux P, Deckmyn H. The humanized anti-glycoprotein Ib monoclonal antibody h6B4-Fab is a potent and safe antithrombotic in a high shear rate arterial thrombosis model in baboons. J Thromb Haemost 2008;100:670–677
   Web of Science ®Google Scholar
• Ulrichts H, Silence K, Schoolmeester A, De Jaegere P, Rossenu S, Roodt J, Priem S, Lauwereys M, Casteels P, Van Bockstaele F, et al. Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with current marketed antiplatelet drugs. Blood 2011;118:757–765
   PubMed Web of Science ®Google Scholar
• Feys H, Roodt J, Vandeputte N, Pareyn I, Mottl H, Hou S, Lamprecht S, Van Rensburg W J, Deckmyn H, Vanhoorelbeke K. Inhibition of von Willebrand factor-platelet glycoprotein Ib interaction prevents and reverses symptoms of acute acquired thrombotic thrombocytopenic purpura in baboons. Blood 2012;120:3611–3614
   PubMed Web of Science ®Google Scholar
• Callewaert F, Roodt JP, Ulrichts H, Stohr T, Janse van Rensburg W, Lamprecht S, Rossenu S, Priem S, Willems W, Holz JB. Evaluation of efficacy and safety of the anti-vWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura. Blood 2012;120:3603–3610
   PubMed Web of Science ®Google Scholar
• Fortman JD, Hewett TA, Bennett BT. Important biological features. In: The laboratory nonhuman primate. Boca Raton: CRC Press, 2002: 1–34
   Google Scholar
• Hoffbrand AV, Moss PAH, Pettit JE. Platelets, blood coagulation and haemostasis. In: Essential haematology. 5th edn. Oxford: Blackwell Publishing, 2006: 265–269
   Google Scholar
• Labea PJ, Pretorius PJ. Newborn secreening for classic galactosaemia and primary congenital hypothyroidism in the Nkangala district of Mpumalanga Province of South Africa. S Afr J Child Health 2008;2:19–22
   Google Scholar
• Primer3Plus. [Online] Available: http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi/. [Accessed 13 June 2013]
   Google Scholar
• GPVI. Transcript ID: ENST00000417454 [Online] Available: http://www.ensembl.org/Homo_sapiens/Transcript/Sequence_cDNA?db=core;g=ENSG00000088053;r=19:55525073-55. Updated February 2014. [Accessed 25 March 2014]
   Google Scholar
• Chromas Lite. [Online] Available: http://chromas-lite.software.informer.com/2.0. [Accessed 26 March 2014]
   Google Scholar
• Lalign. [Online] Available: www.ch.embnet.org/software/LALIGN_form.html. [Accessed 26 March 2014]
   Google Scholar
• Huang X, Miller W. A time-efficient, linear-space local similarity algorithm. Adv Appl Math 1991;12:337–357
   Web of Science ®Google Scholar
• ExPASy translate tool. [Online] Available: http://web.expasy.org/translate. [Accessed 26 March 2014]
   Google Scholar
• Al-Tamimi M, Mu F, Arthur JF, Shen Y, Moroi M, Berndt MC, Andrews RK, Gardiner EE. Anti-glycoprotein VI monoclonal antibodies directly aggregate platelets independently of FcRIIa and induce GPVI ectodomain shedding. Platelets 2009; 20:75–82
   PubMed Web of Science ®Google Scholar
• Clemetson JM, Polgar J, Magnenat E, Wells TNC, Clemetson KJ. The platelet collagen receptor glycoprotein VI is a member of the immunoglobulin superfamily closely related to FcαR and the natural killer receptors. J Biol Chem 1999;274:29019–29024
   PubMed Web of Science ®Google Scholar
• Smethurst PA, Joutsi-Korhonen L, O’Connor MN, Wilson E, Jennings NS, Garner SF, Zhang Y, Knight CG, Dafforn TR, Buckle A, et al. Identification of the primary collagen-binding surface on human glycoprotein VI by site-directed mutagenesis and by a blocking phage antibody. Blood 2004;103:903–911
   PubMed Web of Science ®Google Scholar
• Lecut C, Arocas V, Ulrichts H, Elbaz A, Villeval JL, Lacapère JJ, Deckmyn H, Jandrot-Perrus M. Identification of residues within human glycoprotein VI involved in the binding to collagen. J Biol Chem 2004;279:52293–52299
   PubMed Web of Science ®Google Scholar
• Stave JW, Lindpainter K. Antibody and Antigen Contact Residues Define Epitope and Paratope Size and Structure. J Immunol 2013;191:1428–1435
   PubMed Web of Science ®Google Scholar
• O’Connor MN, Smethurst PA, Farndale RW, Ouwehand WH. Gain- and loss-of-function mutants confirm the importance of apical residues to the primary interaction of human glycoprotein VI with collagen. J Thromb Haemost 2006;4:869–873
   PubMed Web of Science ®Google Scholar
• Suzuki-Inoue K, Tulasne D, Shen Y, Bori-Sanz T, Inoue O, Jung SM, Moroi M, Andrews RK, Berndt MC, Watson SP. Association of Fyn and Lyn with the Proline-rich Domain of Glycoprotein VI Regulates Intracellular Signaling. J Bio Chem 2002;277:21561–21566
   PubMed Web of Science ®Google Scholar
• Horii K, Kahn ML, Herr AB. Structural basis for platelet collagen responses by the immune-type receptor glycoprotein VI. Blood. 2006;108:936–942
   PubMed Web of Science ®Google Scholar